certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-22 and is reviewed periodically as new material appears.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
=== Lactic acidosis === Because of concerns about potential lactic acidosis, as of 2026 the US Food and Drug Administration (FDA) recommends avoiding the use of metformin in more severe chronic kidney disease, below the eGFR cutoff of 30 mL/minute/1.73 m2. Lactate uptake by the liver is diminished with metformin use because lactate is a substrate for hepatic gluconeogenesis, a process that metformin inhibits. In healthy individuals, this slight excess is cleared by other mechanisms (including uptake by unimpaired kidneys), and no significant elevation in blood levels of lactate occurs. However, when kidney function is severely impaired, clearance of metformin and lactate is reduced, increasing levels of both, and possibly causing lactic acid buildup. Because metformin decreases liver uptake of lactate, metformin is also contraindicated in any other condition that may precipitate lactic acidosis; including alcoholism (due to depletion of NAD+ stores), heart failure, and respiratory disease (due to inadequate tissue oxygenation); the most common cause is kidney disease. In people with mild to moderate chronic kidney disease, metformin is generally safe, although a proportional reduction of metformin dose is recommended, according to severity of estimated glomerular filtration rate (eGFR) and with periodic reassessment of kidney function, (e.g., periodic plasma creatinine measurement). Lactic acidosis rarely occurs with metformin exposure during routine medical care.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
is called the cumulative liquid intake, with the dimension of length. The wetted length of the bar, that is the distance between the wetted end of the bar and the so-called wet front, is dependent on the fraction f of the volume occupied by voids. This number f is the porosity of the medium; the wetted length is then
is the mass of the solids. For materials that change in volume with water content, such as coal, the gravimetric water content, u, is expressed in terms of the mass of water per unit mass of the moist specimen (before drying):
Monitoring a person's health over time after treatment. This includes keeping track of the health of people who participate in a clinical study or clinical trial for a period of time, both during the study and after the study ends. (NCI) Food and Drug Administration (FDA)
Sources: en.wikipedia.org
Target proteins or DNA sequences are immobilized to the wells of a microtiter plate. Many genetic sequences are expressed in a bacteriophage library in the form of fusions with the bacteriophage coat protein, so that they are displayed on the surface of the viral particle. The protein displayed corresponds to the genetic sequence within the phage. This phage-display library is added to the dish and after allowing the phage time to bind, the dish is washed. Phage-displaying proteins that interact with the target molecules remain attached to the dish, while all others are washed away. Attached phage may be eluted and used to create more phage by infection of suitable bacterial hosts. The new phage constitutes an enriched mixture, containing considerably less irrelevant phage (i.e. non-binding) than were present in the initial mixture. Steps 3 to 5 are optionally repeated one or more times, further enriching the phage library in binding proteins. Following further bacterial-based amplification, the DNA within the interacting phage is sequenced to identify the interacting proteins or protein fragments.
acid 1. (Brønsted–Lowry acid) Any chemical species or molecular entity that acts as a proton donor when reacting with another species, because it loses at least one proton (H+) which is then transferred or 'donated' to the other species, which by definition is a Brønsted–Lowry base. When dissolved in an aqueous solution, a proton donor which increases the concentration of hydronium ion (H3O+) by transferring protons to water molecules may also be called an Arrhenius acid. The term "acid", when not otherwise qualified, often refers implicitly to a Brønsted–Lowry acid. 2. (Lewis acid) Any chemical species or molecular entity that acts as an electron pair acceptor when reacting with another species, forming a covalent bond by accepting a lone pair of electrons donated by the other species, which is known as a Lewis base. This definition was intended as a generalization of the Brønsted–Lowry definition by proposing that acid-base reactions are best viewed as reorganizations of electrons rather than transfers of protons, with the acid being a species that accepts electron pairs from another species either directly or by releasing protons (H+) into the solution, which then accept electron pairs from the other species. The Lewis definition is inclusive of many Brønsted–Lowry acids, though not all: most Lewis acids are not Brønsted–Lowry acids, and most Brønsted–Lowry acids are not Lewis acids. 3. Colloquially, any compound which, when dissolved in water, yields a pH of less than 7.0.
For voluntary service to St John Ambulance in London. Bronagh Mary Hegarty. Covid-19 Principal Pharmacist for Patient Services and Procurement, Western Health and Social Care Trust. For services to Healthcare and Pharmacy. Ian Bruce Henderson. Councillor, Kensington and Chelsea London Borough Council. For services to the community in the Royal Borough of Kensington and Chelsea. Jacqueline Ann Hendra. Social Care Assessor, Devon County Council. For services to People with Disabilities. Robert Patrick Hendry. Custodian, Prime Minister's Office. For services to the Prime Minister's Office. Daniel Herman. For services to Education and to Holocaust Awareness. Timothy John Hewer. For services to Beekeeping in Little Stoke, South Gloucestershire. Pauline Higgins. For services to the community in Liverpool, Merseyside. Donald Alexander Hill. For services to the community in County Londonderry. Felicity Ann De Grave Hills. For services to the community in Hastings, East Sussex. Andrew Richard Hinchliff. Lately Member, Conwy County Council. For services to Local Government and to the community in North Wales. Duncan Holden. Cricket Co-ordinator and Safeguarding Officer, Stoke Newington Cricket Club. For services to Sport in London. Ian Watson Holland. Lately Chair and Trustee, Enable Ayr and District SCIO. For services to People with Learning Disabilities in Ayr and Prestwick. Beverly Joan Hopkins. Special Educational Needs Co-ordinator, Palmerston Primary School, Barry. For services to Education, to People with Disabilities and to Sport. The Reverend Christopher Stewart Howson.
In June 2000, Labcorp acquired the laboratory testing business of Pathology Medical Laboratories. In May 2001, Labcorp acquired Path Lab Holdings, the largest regional laboratory in New England. In June 2001, it acquired ViroMed, which specialized on clinical diagnostic testing in virology, molecular biology, serology, microbiology, mycology and mycobacteriology, as well as in tissue and eye bank testing. In 2013, it closed the Viromed facility in Minnetonka, Minnesota and laid off 79 workers. In December 2001, Labcorp became the exclusive marketer for genomics and proteomics tests for breast cancer, colon cancer, melanoma, and hypertension made by Myriad Genetics. In March 2002, Roche sold its remaining interest in the company. In May 2002, Labcorp acquired Dynacare, a Canadian medical laboratory services company, for $480 million. In January 2003, Labcorp acquired Dianon, a provider of oncology and genomic diagnostic testing services, for $598 million in cash. In February 2005, the company acquired US Pathology Labs Inc., a provider of anatomical pathology and oncology testing services, for $155 million. In March 2005, Labcorp acquired Esoterix, a provider of specialty reference testing, for approximately $150 million in cash from Behrman Capital. In November 2006, Labcorp acquired Litholink, a kidney stone analysis laboratory. In January 2008, Labcorp acquired Tandem Labs, a contract research organization specializing in advanced mass spectrometry, immunoanalytical support, pharmacokinetics, and pharmacodynamics.
Sources: en.wikipedia.org
In 2001, various tyrannosaurid teeth and a metatarsal unearthed in a quarry near Zhucheng, China, were assigned by Chinese paleontologist Hu Chengzhi to the newly erected species Tyrannosaurus zhuchengensis. However, in a nearby site, a right maxilla and left jawbone were assigned to the newly erected tyrannosaurid genus Zhuchengtyrannus in 2011. It is possible that T. zhuchengensis is synonymous with Zhuchengtyrannus. In any case, T. zhuchengensis is considered to be a nomen dubium as the holotype lacks diagnostic features below the level Tyrannosaurinae. In 2006, a fragmentary tyrannosaurid lacrimal (CM 9401) from the Judith River Formation of Fergus County, Montana, was described as ?Tyrannosaurus sp. This isolated right lacrimal was originally collected alongside the holotype specimen of Deinosuchus rugosus, a giant crocodilian, and remained undescribed until its re-identification as belonging to a tyrannosaurid theropod in the 1980s by paleontologist Dale Russell. The lacrimal closely resembles those of Tyrannosaurus rex in both size and morphology. Notably, it lacks the "lacrimal horn" typically present in earlier tyrannosaurids like Albertosaurus and Gorgosaurus, instead exhibiting a distinct rugosity along the dorsal surface—consistent with T. rex and its Asian relative Tarbosaurus. The specimen's considerable size places it within the range of known T. rex individuals, suggesting the presence of large tyrannosaurids during the Campanian stage (~75 million years ago), a temporal range earlier than the established Maastrichtian age (~68–66 Ma) for Tyrannosaurus rex.
"Osteogenesis Imperfecta Overview". NIH Osteoporosis and Related Bone Diseases. National Resource Center, National Institutes of Health, U.S. Department of Health and Human Services. 8 May 2023. Archived from the original on 4 October 2017.
The company laid off an unspecified number of staffers in March 2005, although Kudirka denied rumors that the company was closing. He soon dissolved 2015 and moved to Florida, returning to Tulsa when he realized he wanted to continue working on video games. Konami Digital Entertainment released Time Ace, developed under the Trainwreck Studios name, in June 2007. On September 24, 2008, Kudirka announced that 2015 had received "several million dollars" in funding from private investors, with which it opened another division, Tornado Studios. The new studio started out with two people, including Kudirka, and sought to make casual games, including for the Wii. At the same time, 2015 was to continue making action games. By March 2009, Tornado Studios had 15 employees and was nearing the release of its first game, Powerbike, through Majesco. The game was released in April under the Trainwreck Studios name. Its first game was Project Runway, initially called World of Fashion until Atari signed to publish it and licensed the series's name. It was released in March 2010. In November, Tornado Studios released Fun with Death for iOS devices. Kudirka said that the rise of digital distribution allowed Tornado Studios to self-publish its games, aiming to release as many games as possible. A third game, Anomaly for personal computers and for the PlayStation 3 via PlayStation Network, was two-thirds-complete by this time and scheduled to be released by April 1, 2011. Tornado Studios had 25 employees, including contractors, at this time.
== Taxonomy == The species was originally described based on female morphology, being a member of Polyphaga, while the males were described as a separate species, Homœogamia sinensis. Further and re-examination resulted in Eupolyphaga sinensis being established. Historically males were confused with the species E. thibetana and E. yunnanensis, they are now recognized as separate species, having morphological differences that distinguish them. E. sinensis was the first member of the family Corydiidae (at the time referred to as Polyphagidae) to have its mitochondrial DNA sequenced.
=== Death and legacy === Several retrospective sources state that Liu was greatly saddened by Zhou Enlai's death in January 1976 and, according to Guangming Daily, even had himself carried on a stretcher to the Beijing Hospital to bid farewell to Zhou's remains. Having been diagnosed with cancer in 1975, Liu's own health deteriorated shortly after, and he died of his illness in Beijing on June 24, 1976. He was 81. His memorial service was held at the Babaoshan Revolutionary Cemetery and was presided by Vice Premier and general Chen Xilian. The June 30, 1976 issue of the People's Daily reported that Vice Chairperson Li Suwen delivered Liu's eulogy. According to the eulogy, Liu Wenhui supported Chairman Mao, the Cultural Revolution, the movement to criticize Lin Biao and Confucius, and finally the ongoing campaign against Deng Xiaoping. He had also called for the liberation of Taiwan from Kuomintang rule. Present at his funeral were several politicians including Wu De, Li Jingquan, Ngapoi Ngawang Jigme, and Zhou Jianren, among others. Marshals Zhu De, Ye Jianying, and Liu Bocheng sent wreaths to the funeral, as well as Hua Guofeng and Song Qingling.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.